Loading...
Bristol-Myers Squibb Company Ce
CELG-RI•NYSE
HealthcareDrug Manufacturers - General
$0.03
$-0.00(-0.39%)
Bristol-Myers Squibb Company Ce (CELG-RI) Stock Overview
Explore Bristol-Myers Squibb Company Ce’s financial performance, market position, analyst ratings, and future outlook.
Revenue Growth
7.32%
↑ 7.32%
Profit Growth
$2.67
↓ 211.50%
EPS Growth
$2.67
↓ 213.66%
Operating Margin
18.45%
↓ 100.00%
ROE
31.93%
↓ 211.50%
Dividend Yield
0.00%
↑ 4.63%
Analyst Recommendations data is not available for CELG-RIAnalyst Recommendations details for CELG-RI are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Company Profile
Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies. The company was founded in August 1933 and is headquartered in Princeton, NJ.
Employees
34,100
Headquarters
Princeton, DE
Founded
1970